{"id":13659,"date":"2020-06-30T15:56:55","date_gmt":"2020-06-30T12:56:55","guid":{"rendered":"https:\/\/oncology.med.sumdu.edu.ua\/scientific-articles\/publications-in-scopus\/"},"modified":"2025-09-08T22:45:17","modified_gmt":"2025-09-08T19:45:17","slug":"publications-in-scopus","status":"publish","type":"page","link":"https:\/\/oncology.med.sumdu.edu.ua\/en\/scientific-articles\/publications-in-scopus\/","title":{"rendered":"Publications in Scopus"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
<\/div>\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

SCIENTIFIC WORK<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Department of Oncology and Radiology<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

public information<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Publications Scopus<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\tGeneral list of publications<\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t

1.Rare complication of the Lewis operation | Redkoe oslozhnenie operatsii L’iuisa.
Vinnichenko, A.A., Vinnichenko, I.A., Moskalenko, V.L., Korobe\u01d0nik, V.I. Klinicheskaya Khirurgiya, 1990, (10), pp. 53<\/p>

2. Experience with gastro- and enterostomy in esophageal obstruction | Opyt gastro- i \u00e9nterostomii pri neprokhodimosti pishchevoda.
Vinnichenko, A.A., Vinnichenko, I.A., Vataman, V.N. Klinicheskaya Khirurgiya, 1991, (10), pp. 30\u201332<\/p>

3. Surgical treatment of thoracic esophageal obstruction of neoplastic genesis | Khirurgicheskoe lechenie neprokhodimosti grudnoi chasti pishchevoda opukholevogo geneza.
Veligotski\u01d0, N.N., Florikian, A.K., Teslenko, I.V., …Vinnichenko, I.A., Veligotski\u01d0, A.N. Klinicheskaya Khirurgiya, 1999, (8), pp. 11\u201313<\/p>

4. Platinum-based chemotherapy plus cetuximab in head and neck cancer
Vermorken, J.B., Mesia, R., Rivera, F., …Amellal, N., Hitt, R. New England Journal of Medicine, 2008, 359(11), pp. 1116\u20131127<\/p>

5. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
Pirker, R., Pereira, J.R., Szczesna, A., …Emig, M., Gatzemeier, U. The Lancet, 2009, 373(9674), pp. 1525\u20131531<\/p>

6. Multicenter phase III comparison of cisplatin\/S-1 with cisplatin\/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: The FLAGS trial
Ajani, J.A., Rodriguez, W., Bodoky, G., …Lang, I., Falcon, S. Journal of Clinical Oncology, 2010, 28(9), pp. 1547\u20131553<\/p>

7. First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: A subgroup analysis of data from the FLEX phase 3 study
Gatzemeier, U., von Pawel, J., Vynnychenko, I., …O’Byrne, K.J., Pirker, R. The Lancet Oncology, 2011, 12(1), pp. 30\u201337<\/p>

8. [Spermatogenic function under the influence of heavy metal salts and its correction by preparation Tivortin].
Romaniuk, A.M., Sauliak, S.V., Moskalenko, R.A., Moskalenko, I.V. Likars’ka sprava \/ Ministerstvo okhorony zdorov’ia Ukra\u00efny, 2012, (1-2), pp. 123\u2013128<\/p>

9. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: Final results of a phase III trial
Socinski, M.A., Bondarenko, I., Karaseva, N.A., …Iglesias, J.L., Renschler, M.F. Journal of Clinical Oncology, 2012, 30(17), pp. 2055\u20132062<\/p>

10. Prognostic factors in patients with advanced non-small cell lung cancer: Data from the phase III FLEX study
Pirker, R., Pereira, J.R., Szczesna, A., …O’Byrne, K.J., Gatzemeier, U. Lung Cancer, 2012, 77(2), pp. 376\u2013382<\/p>

11. International, randomized, placebo-controlled, double-blindphase III study of motesanib plus carboplatin\/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1
Scagliotti, G.V., Vynnychenko, I., Park, K., …Galimi, F., Spigel, D.R. Journal of Clinical Oncology, 2012, 30(23), pp. 2829\u20132836<\/p>

12. Medical discourse in pathological anatomy.
Moskalenko, R., Tatsenko, N., Romanyuk, A., Perelomova, O., Moskalenko, Y. Georgian medical news, 2012, (206), pp. 63\u201366<\/p>

13. [Vascular-parenchymal ratio of testes under correction of exposure to combinations of heavy metals salts].
Romaniuk, A.M., Moskalenko, I.V., Sauliak, S.V., Bonchev, S.D., Moskalenko, R.A. Likars’ka sprava \/ Ministerstvo okhorony zdorov’ia Ukra\u00efny, 2013, (4), pp. 122\u2013127<\/p>

14. Motesanib plus carboplatin\/paclitaxel in patients with advanced squamous non-small-cell lung cancer results from the randomized controlled MONET1 study
Novello, S., Scagliotti, G.V., Sydorenko, O., …Hei, Y.-J., Spigel, D.R. Journal of Thoracic Oncology, 2014, 9(8), pp. 1154\u20131161<\/p>

15. An open-label, multicenter, randomized phase Ib\/II study of eribulin mesylate administered in combination with pemetrexed versus pemetrexed alone as second-line therapy in patients with advanced nonsquamous non-small-cell lung cancer
Waller, C.F., Vynnychenko, I., Bondarenko, I., …Shelton, M.J., Dave, H. Clinical Lung Cancer, 2015, 16(2), pp. 92\u201399<\/p>

16. Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin\/S-1 Versus Cisplatin\/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS)
Bodoky, G., Scheulen, M.E., Rivera, F., …Cascinu, S., Ajani, J.A. Journal of Gastrointestinal Cancer, 2015, 46(2), pp. 109\u2013117<\/p>

17. \u0413\u043e\u0440\u043c\u043e\u043d\u0430\u043b\u044c\u043d\u043e-\u0433\u0435\u043d\u0435\u0442\u0438\u0447\u043d\u0438\u0439 \u0441\u043a\u0440\u0438\u043d\u0456\u043d\u0433 \u0443 \u0445\u0432\u043e\u0440\u0438\u0445 \u0437\u0430 \u0432\u0438\u0440\u0430\u0437\u043a\u043e\u0432\u043e\u0457 \u0433\u0430\u0441\u0442\u0440\u043e\u0434\u0443\u043e\u0434\u0435\u043d\u0430\u043b\u044c\u043d\u043e\u0457 \u043a\u0440\u043e\u0432\u043e\u0442\u0435\u0447\u0456 \/ \u0414\u0443\u0436\u0438\u0439 \u0406. \u0414., \u0420\u043e\u043c\u0430\u043d\u044e\u043a \u0410. \u041c., \u041b\u0438\u043d\u0434\u0456\u043d \u041c. \u0421., \u0428\u0435\u0432\u0447\u0435\u043d\u043a\u043e \u042e.\u042e. \/\/ \u041a\u043b\u0456\u043d\u0456\u0447\u043d\u0430 \u0445\u0456\u0440\u0443\u0440\u0433\u0456\u044f. \u2013 \u041a\u0438\u0457\u0432: \u0422\u041e\u0412 \u00ab\u041b\u0456\u0433\u0430 \u2013 \u0406\u043d\u0444\u043e\u0440\u043c\u00bb, 2015. \u2013 \u2116 11 \u2013 \u0421. 24-27.<\/p>

18. Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)-positive metastatic breast cancer: A randomized clinical trial
Rugo, H.S., Barve, A., Waller, C.F., …Yanez Ruiz, E.P., Pennella, E. JAMA – Journal of the American Medical Association, 2017, 317(1), pp. 37\u201347<\/p>

19. The features of morphological changes in the urinary bladder under combined effect of heavy metal salts
Romaniuk, A., Sikora, V., Lyndin, M., …Gyryavenko, N., Korobchanska, A. Interventional Medicine and Applied Science, 2017, 9(2), pp. 105\u2013111<\/p>

20. Anatomical and morphological aspects of papillae, epithelium, muscles, and glands of rats’ tongue: Light, scanning, and transmission electron microscopic study
Davydova, L., Tkach, G., Tymoshenko, A., …Maksymova, O., Suchonos, O. Interventional Medicine and Applied Science, 2017, 9(3), pp. 168\u2013177<\/p>

21. Primary multiple tumor with affection of the thyroid gland, uterus, urinary bladder, mammary gland and other organs
Romaniuk, \u0410., Lyndin, M., Smiyanov, V., …Sikora, V., Gladchenko, O. Pathology Research and Practice, 2017, 213(5), pp. 574\u2013579<\/p>

22. 12 years of fighting liposarcoma: a case report
Kononenko, M., Vynnychenko, I., Moskalenko, Y., Vynnychenko, O. Wiadomosci lekarskie (Warsaw, Poland : 1960), 2017, 70(5), pp. 995\u2013997<\/p>

23. Eye retinal changes under the influence of chromium ions
Kuzenko, Y.V., Kuzenko, O.V., Dyomin, Y.A. Oftalmologicheskii Zhurnal, 2018, (1), pp. 67\u201373<\/p>

24. Ecological causality of the central serous chorioretinopathy incidence in the Sumy region
Kuzenko, O.V., Dyomin, Yu.A., Litvinova, L.V., Kuzenko, E.V. Oftalmologicheskii Zhurnal, 2018, (3), pp. 63\u201367<\/p>

25. Effect of heavy metals on the readaptive processes in the urinary bladder
Romaniuk, A., Sikora, V., L\u0443nd\u0456na, Y., …Piddubnyi, A., Miroshnichenko, M. Bangladesh Journal of Medical Science, 2019, 18(1), pp. 100\u2013106<\/p>

26. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma<\/p>

Rini, B.I., Plimack, E.R., Stus, V., …Atkins, M.B., Powles, T. New England Journal of Medicine, 2019, 380(12), pp. 1116\u20131127<\/p>

27. Prostate cancer with intraluminal inclusions: The association of the immunophenotype with grade score
Pidddubnyi, A., Romaniuk, A., Radomychelski, I.-M., Moskalenko, Y., Moskalenko, R.A. Iranian Journal of Pathology, 2019, 14(3), pp. 212\u2013222<\/p>

28. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Mok, T.S.K., Wu, Y.-L., Kudaba, I., …Nguyen, T.Q., Pham, X.D. The Lancet, 2019, 393(10183), pp. 1819\u20131830<\/p>

29. Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Paz-Ares, L., Dvorkin, M., Chen, Y., …Sumey, C., Williamson, M. The Lancet, 2019, 394(10212), pp. 1929\u20131939<\/p>

30. Morphological Characteristics and Correction of Long Tubular Bone Regeneration under Chronic Hyperglycemia Influence Dudchenko, Y.S., Maksymova, O.S., Pikaliuk, V.S., …Kyptenko, L.I., Tkach, G.F. Analytical Cellular Pathology, 2020, 2020, 5472841<\/p>

31. Vynnychenko I.O., Pryvalova A.\u041e., Vynnychenko O.I., L\u0443nd\u0456n M.S., Sikora V.V., Romaniuk A.M. (2020). PIK3CA-mutant circulating tumor DNA in patients with breast cancer. Azerbaijan Medical Journal, 3, 79-88. ISSN 0005-2523. https:\/\/doi.org\/10.34921\/amj.2020.3.010<\/p>

32. Case report of giant nonmetastatic gastrointestinal solid tumor without clinical manifestations in a middle-aged male patient
Vynnychenko, I., Kononenko, M., Smorodska, O., …Lyndin, M., Romaniuk, A. Novosti Khirurgii, 2020, 28(5), pp. 597\u2013602<\/p>

33. PIK3CA-Mutant circulating tumor dna in patients with breast cancer | S\u00dcd v\u0186z\u0130s\u0130 x\u0186r\u00c7\u0186ng\u0130 olan x\u0186st\u0186l\u0186rd\u0186 mutant pik3ka \u21d3 s\u0130rkulyas\u0130ya ed\u0186n \u015e\u0130\u015e dnt-si
Vynnychenko, I.O., Pryvalova, A.\u041e., Vynnychenko, O.I., …Sikora, V.V., Romaniuk, A.M. Azerbaijan Medical Journal, 2020, (3), pp. 79\u201388<\/p>

34. Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Adults with Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial
Blayney, D.W., Zhang, Q., Feng, J., …Huang, L., Shi, Y.-K. JAMA Oncology, 2020, 6(11), e204429<\/p>

35. Case report of giant nonmetastatic gastrointestinal solid tumor without clinical manifestations in a middle-aged male patient
Vynnychenko, I., Kononenko, M., Smorodska, O., …Lyndin, M., Romaniuk, A. Novosti Khirurgii, 2020, 28(5), pp. 597\u2013602<\/p>

36. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study
Ferris, R.L., Haddad, R., Even, C., …Fayette, J., Licitra, L. Annals of Oncology, 2020, 31(7), pp. 942\u2013950<\/p>

37. Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial
Jotte, R., Cappuzzo, F., Vynnychenko, I., …Sandler, A., Socinski, M.A.Journal of Thoracic Oncology, 2020, 15(8), pp. 1351\u20131360<\/p>

38. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
Powles, T., Plimack, E.R., Souli\u00e8res, D., …Atkins, M.B., Rini, B.I. The Lancet Oncology, 2020, 21(12), pp. 1563\u20131573<\/p>

39. Morphological and Crystal-Chemical Features of Macro- And Microcalcifications of Human Aorta
Radomychelski, I.-M., Piddubnyi, A., Danilchenko, S., …Moskalenko, Y., Moskalenko, R. Microscopy and Microanalysis, 2021<\/p>

40. Durvalumab, with or without tremelimumab, plus platinum\u2013etoposide versus platinum\u2013etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
Goldman, J.W., Dvorkin, M., Chen, Y., …Wang, K., Chen, Z. The Lancet Oncology, 2021, 22(1), pp. 51\u201365<\/p>

41. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma
Sahin, U., T\u00fcreci, \u00d6., Manikhas, G., …Schuler, M., Al-Batran, S.-E. Annals of Oncology, 2021, 32(5), pp. 609\u2013619<\/p>

42. MODERN VECTOR in TREATMENT of PATIENTS with LUNG CANCER: TYROSINE KINASE INHIBITORS in EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS (literature review) | \u0421\u0443\u0447\u0430\u0441\u043d\u0438\u0439 \u0432\u0435\u043a\u0442\u043e\u0440 \u0443 \u043b\u0456\u043a\u0443\u0432\u0430\u043d\u043d\u0456 \u043f\u0430\u0446\u0456\u0454\u043d\u0442\u0456\u0432, \u0445\u0432\u043e\u0440\u0438\u0445 \u043d\u0430 \u0440\u0430\u043a \u043b\u0435\u0433\u0435\u043d\u0456\u0432: \u0456\u043d\u0433\u0456\u0431\u0456\u0442\u043e\u0440\u0438 \u0442\u0438\u0440\u043e\u0437\u0438\u043d \u043a\u0456\u043d\u0430\u0437\u0438 \u043f\u0440\u0438 EGFR \u043c\u0443\u0442\u0430\u0446\u0456\u044f\u0445 (\u043e\u0433\u043b\u044f\u0434 \u043b\u0456\u0442\u0435\u0440\u0430\u0442\u0443\u0440\u0438)
Smorodska, O.M., Moskalenko, Yu.V., Vynnychenko, I.O., Vynnychenko, O.I., Kostuchenko, V.V. Medicni Perspektivi, 2021, 26(2), pp. 4\u201311<\/p>

43. Investigating the protective capacity of polymethylsiloxane polyhydrate against chromium (VI)-induced neurotoxicity of the rat optic nerve
Kuzenko, O.V., Dyomin, Y.A., Kuzenko, E.V. Oftalmologicheskii Zhurnal, 2021, 90(1), pp. 62\u201369<\/p>

44. Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer
Rugo, H.S., Pennella, E.J., Gopalakrishnan, U., …Fuentes-Alburo, A., Waller, C.F. Breast Cancer Research and Treatment, 2021, 188(2), pp. 369\u2013377<\/p>

45. Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial
Rugo, H.S., Pennella, E.J., Gopalakrishnan, U., …Barve, A., Waller, C.F. Breast, 2021, 58, pp. 18\u201326<\/p>

46. Intestinal microbiota in Alzheimer\u2019s disease \/ \u0422. Ivakhniuk, Yu. Ivakhniuk \/\/ Georgian Medical News. – \u2116 4 (313). \u2013 2021. \u2013 \u0420. 94-98<\/p>

47. Standardization Issues of Test Methods for Engineering Nanomaterials \/ K. Dyadyura, L. Hrebenyk, \u0422. Ivakhniuk, Yu. Ivakhniuk, L. Sukhodub \/\/ Abstract book 2 nd Grabchenko\u2019s internationalconference on advanced manufacturing processes \u2013 InterPartner, LNME \u2013 2021. \u2013 P. 797-805<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t

\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\tVynnychenko I.<\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t

Scopus Author ID:<\/strong> https:\/\/www.scopus.com\/authid\/detail.uri?authorId=24781268000<\/a><\/span><\/p>\n

h-index:<\/strong> 20<\/p>\n

ORCID ID:<\/strong> https:\/\/orcid.org\/0000-0002-2339-6509<\/a><\/span><\/p>\n

1.Rare complication of the Lewis operation | Redkoe oslozhnenie operatsii L’iuisa.
Vinnichenko, A.A., Vinnichenko, I.A., Moskalenko, V.L., Korobe\u01d0nik, V.I.
Klinicheskaya Khirurgiya, 1990, (10), pp. 53<\/p>\n

2. Experience with gastro- and enterostomy in esophageal obstruction | Opyt gastro- i \u00e9nterostomii pri neprokhodimosti pishchevoda.
Vinnichenko, A.A., Vinnichenko, I.A., Vataman, V.N.
Klinicheskaya Khirurgiya, 1991, (10), pp. 30\u201332<\/p>\n

3. Surgical treatment of thoracic esophageal obstruction of neoplastic genesis | Khirurgicheskoe lechenie neprokhodimosti grudnoi chasti pishchevoda opukholevogo geneza.
Veligotski\u01d0, N.N., Florikian, A.K., Teslenko, I.V., …Vinnichenko, I.A., Veligotski\u01d0, A.N.
Klinicheskaya Khirurgiya, 1999, (8), pp. 11\u201313<\/p>\n

4. Platinum-based chemotherapy plus cetuximab in head and neck cancer
Vermorken, J.B., Mesia, R., Rivera, F., …Amellal, N., Hitt, R.
New England Journal of Medicine, 2008, 359(11), pp. 1116\u20131127<\/p>\n

5. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
Pirker, R., Pereira, J.R., Szczesna, A., …Emig, M., Gatzemeier, U.
The Lancet, 2009, 373(9674), pp. 1525\u20131531<\/p>\n

6. Multicenter phase III comparison of cisplatin\/S-1 with cisplatin\/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: The FLAGS trial
Ajani, J.A., Rodriguez, W., Bodoky, G., …Lang, I., Falcon, S.
Journal of Clinical Oncology, 2010, 28(9), pp. 1547\u20131553<\/p>\n

7. First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: A subgroup analysis of data from the FLEX phase 3 study
Gatzemeier, U., von Pawel, J., Vynnychenko, I., …O’Byrne, K.J., Pirker, R.
The Lancet Oncology, 2011, 12(1), pp. 30\u201337<\/p>\n

8. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: Final results of a phase III trial
Socinski, M.A., Bondarenko, I., Karaseva, N.A., …Iglesias, J.L., Renschler, M.F.
Journal of Clinical Oncology, 2012, 30(17), pp. 2055\u20132062<\/p>\n

9. Prognostic factors in patients with advanced non-small cell lung cancer: Data from the phase III FLEX study
Pirker, R., Pereira, J.R., Szczesna, A., …O’Byrne, K.J., Gatzemeier, U.
Lung Cancer, 2012, 77(2), pp. 376\u2013382<\/p>\n

10. International, randomized, placebo-controlled, double-blindphase III study of motesanib plus carboplatin\/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1
Scagliotti, G.V., Vynnychenko, I., Park, K., …Galimi, F., Spigel, D.R.
Journal of Clinical Oncology, 2012, 30(23), pp. 2829\u20132836<\/p>\n

11. Motesanib plus carboplatin\/paclitaxel in patients with advanced squamous non-small-cell lung cancer results from the randomized controlled MONET1 study
Novello, S., Scagliotti, G.V., Sydorenko, O., …Hei, Y.-J., Spigel, D.R.
Journal of Thoracic Oncology, 2014, 9(8), pp. 1154\u20131161<\/p>\n

12. An open-label, multicenter, randomized phase Ib\/II study of eribulin mesylate administered in combination with pemetrexed versus pemetrexed alone as second-line therapy in patients with advanced nonsquamous non-small-cell lung cancer
Waller, C.F., Vynnychenko, I., Bondarenko, I., …Shelton, M.J., Dave, H.
Clinical Lung Cancer, 2015, 16(2), pp. 92\u201399<\/p>\n

13. Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin\/S-1 Versus Cisplatin\/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS)
Bodoky, G., Scheulen, M.E., Rivera, F., …Cascinu, S., Ajani, J.A.
Journal of Gastrointestinal Cancer, 2015, 46(2), pp. 109\u2013117<\/p>\n

14. 12 years of fighting liposarcoma: a case report
Kononenko, M., Vynnychenko, I., Moskalenko, Y., Vynnychenko, O.
Wiadomosci lekarskie (Warsaw, Poland : 1960), 2017, 70(5), pp. 995\u2013997<\/p>\n

15. Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)-positive metastatic breast cancer: A randomized clinical trial
Rugo, H.S., Barve, A., Waller, C.F., …Yanez Ruiz, E.P., Pennella, E.
JAMA – Journal of the American Medical Association, 2017, 317(1), pp. 37\u201347<\/p>\n

16. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma<\/p>\n

Rini, B.I., Plimack, E.R., Stus, V., …Atkins, M.B., Powles, T.
New England Journal of Medicine, 2019, 380(12), pp. 1116\u20131127<\/p>\n

17. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Mok, T.S.K., Wu, Y.-L., Kudaba, I., …Nguyen, T.Q., Pham, X.D.
The Lancet, 2019, 393(10183), pp. 1819\u20131830<\/p>\n

18. Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Paz-Ares, L., Dvorkin, M., Chen, Y., …Sumey, C., Williamson, M.
The Lancet, 2019, 394(10212), pp. 1929\u20131939<\/p>\n

19. Case report of giant nonmetastatic gastrointestinal solid tumor without clinical manifestations in a middle-aged male patient
Vynnychenko, I., Kononenko, M., Smorodska, O., …Lyndin, M., Romaniuk, A.
Novosti Khirurgii, 2020, 28(5), pp. 597\u2013602<\/p>\n

20. PIK3CA-Mutant circulating tumor dna in patients with breast cancer | S\u00dcd v\u0186z\u0130s\u0130 x\u0186r\u00c7\u0186ng\u0130 olan x\u0186st\u0186l\u0186rd\u0186 mutant pik3ka \u21d3 s\u0130rkulyas\u0130ya ed\u0186n \u015e\u0130\u015e dnt-si
Vynnychenko, I.O., Pryvalova, A.\u041e., Vynnychenko, O.I., …Sikora, V.V., Romaniuk, A.M.
Azerbaijan Medical Journal, 2020, (3), pp. 79\u201388<\/p>\n

21. Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Adults with Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial
Blayney, D.W., Zhang, Q., Feng, J., …Huang, L., Shi, Y.-K.
JAMA Oncology, 2020, 6(11), e204429<\/p>\n

22. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study
Ferris, R.L., Haddad, R., Even, C., …Fayette, J., Licitra, L.
Annals of Oncology, 2020, 31(7), pp. 942\u2013950<\/p>\n

23. Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial
Jotte, R., Cappuzzo, F., Vynnychenko, I., …Sandler, A., Socinski, M.A.
Journal of Thoracic Oncology, 2020, 15(8), pp. 1351\u20131360<\/p>\n

24. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
Powles, T., Plimack, E.R., Souli\u00e8res, D., …Atkins, M.B., Rini, B.I.
The Lancet Oncology, 2020, 21(12), pp. 1563\u20131573<\/p>\n

25. Durvalumab, with or without tremelimumab, plus platinum\u2013etoposide versus platinum\u2013etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
Goldman, J.W., Dvorkin, M., Chen, Y., …Wang, K., Chen, Z.
The Lancet Oncology, 2021, 22(1), pp. 51\u201365<\/p>\n

26. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma
Sahin, U., T\u00fcreci, \u00d6., Manikhas, G., …Schuler, M., Al-Batran, S.-E.
Annals of Oncology, 2021, 32(5), pp. 609\u2013619<\/p>\n

27. MODERN VECTOR in TREATMENT of PATIENTS with LUNG CANCER: TYROSINE KINASE INHIBITORS in EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS (literature review) | \u0421\u0443\u0447\u0430\u0441\u043d\u0438\u0439 \u0432\u0435\u043a\u0442\u043e\u0440 \u0443 \u043b\u0456\u043a\u0443\u0432\u0430\u043d\u043d\u0456 \u043f\u0430\u0446\u0456\u0454\u043d\u0442\u0456\u0432, \u0445\u0432\u043e\u0440\u0438\u0445 \u043d\u0430 \u0440\u0430\u043a \u043b\u0435\u0433\u0435\u043d\u0456\u0432: \u0456\u043d\u0433\u0456\u0431\u0456\u0442\u043e\u0440\u0438 \u0442\u0438\u0440\u043e\u0437\u0438\u043d \u043a\u0456\u043d\u0430\u0437\u0438 \u043f\u0440\u0438 EGFR \u043c\u0443\u0442\u0430\u0446\u0456\u044f\u0445 (\u043e\u0433\u043b\u044f\u0434 \u043b\u0456\u0442\u0435\u0440\u0430\u0442\u0443\u0440\u0438)
Smorodska, O.M., Moskalenko, Yu.V., Vynnychenko, I.O., Vynnychenko, O.I., Kostuchenko, V.V.
Medicni Perspektivi, 2021, 26(2), pp. 4\u201311<\/p>\n

28. Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer
Rugo, H.S., Pennella, E.J., Gopalakrishnan, U., …Fuentes-Alburo, A., Waller, C.F.
Breast Cancer Research and Treatment, 2021, 188(2), pp. 369\u2013377<\/p>\n

29. Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial
Rugo, H.S., Pennella, E.J., Gopalakrishnan, U., …Barve, A., Waller, C.F.
Breast, 2021, 58, pp. 18\u201326<\/p>\n

30 Moskalenko Y, Kurochkin A, Vynnychenko I, Kravets O, Piddubnyi A, Moskalenko R, Potapov O. Toluidine blue for the detection of sentinel lymph nodes in patients with thyroid cancer. Contemp Oncol (Pozn). 2022;26(4):259-267. doi: 10.5114\/wo.2022.124585. Epub 2022 Dec 30. PMID: 36816393; PMCID: PMC9933357.<\/p>\n

31. Shah, M. A., Udrea, A. A., Bondarenko, I., Mansoor, W., S\u00e1nchez, R. G., Sarosiek, T., \u2026 & Ajani, J. A. (2022). Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric\/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies. Cancers<\/em>, 14<\/em>(5), 1168.<\/p>\n

32. Bedke, J., Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Waddell, T., \u2026 & Powles, T. (2022). Health-related quality of life analysis from KEYNOTE-426: pembrolizumab plus axitinib versus sunitinib for advanced renal cell carcinoma. European Urology<\/em>, 82<\/em>(4), 427-439.<\/p>\n

33. de Castro Jr, G., Rizvi, N. A., Schmid, P., Syrigos, K., Martin, C., Yamamoto, N., \u2026 & NEPTUNE Investigators. (2023). NEPTUNE: phase 3 study of first-line Durvalumab plus tremelimumab in patients with metastatic NSCLC. Journal of Thoracic Oncology<\/em>, 18<\/em>(1), 106-119.<\/p>\n

34. Psyrri, A., Fayette, J., Harrington, K., Gillison, M., Ahn, M. J., Takahashi, S., \u2026 & KESTREL Investigators. (2023). Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study. Annals of Oncology<\/em>, 34<\/em>(3), 262-274.<\/p>\n

35. Ren, S., Feng, J., Ma, S., Chen, H., Ma, Z., Huang, C., \u2026 & Zhou, C. (2023). KEYNOTE\u2010033: randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD\u2010L1\u2010positive, advanced NSCLC. International Journal of Cancer<\/em>, 153<\/em>(3), 623-634.<\/p>\n

36. Plimack, E. R., Powles, T., Stus, V., Gafanov, R., Nosov, D., Waddell, T., \u2026 & Rini, B. I. (2023). Pembrolizumab Plus Axitinib Versus Sunitinib as First-Line Treatment of Advanced Renal Cell Carcinoma: 43-Month Follow-up of the Phase 3 KEYNOTE-426 Study. European Urology<\/em>, 84<\/em>(5), 449-454.<\/p>\n

37. Plimack, E. R., Powles, T., Stus, V., Gafanov, R., Nosov, D., Waddell, T., \u2026 & Rini, B. I. (2023). Corrigendum to\u201d Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study\u201d[Eur. (2023)]. European urology<\/em>, 84<\/em>(5), e123-e124.<\/p>\n

38. Corrigendum to \u201cPembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study\u201d [Eur. Urol. (2023)] Primack, Elizabeth R. et al. European Urology, Volume 84, Issue 5, e123 – e124.<\/p>\n

39. <\/span>Felip E, Altorki N, Zhou C, Valli\u00e8res E, Csoszi T,
Vynnychenko IO, Goloborodko O, Rittmeyer A, Reck M, Martinez-Marti A, Kenmotsu
H, Chen YM, Chella A, Sugawara S, Fu C, Ballinger M, Deng Y, Srivastava MK,
Bennett E, Gitlitz BJ, Wakelee HA; IMpower010 Study Investigators. Five-Year
Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage
IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized,
Phase III Trial. J Clin Oncol. 2025 Jul 20;43(21):2343-2349. doi:
10.1200\/JCO-24-01681. <\/span><\/p>\n

40. Rini BI, Plimack ER, Stus V, Gafanov R, Waddell T,
Nosov D, Pouliot F, Alekseev B, Souli\u00e8res D, Melichar B, Vynnychenko I, de
Azevedo SJ, Borchiellini D, McDermott RS, Bedke J, Tamada S, Wu S, Markensohn
J, Zhang Y, Loboda A, Vajdi A, Perini RF, Burgents J, Powles T. Pembrolizumab
plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma:
5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial. Nat
Med. 2025 Aug 1. doi: 10.1038\/s41591-025-03867-5. <\/span><\/p>\n

41. Kostiuchenko, V.,
Vynnychenko, I., Moskalenko, Y., & Pohorila, V. (2025). Detection of
postoperative recurrence in colorectal cancer: Exploring the value of liquid
biopsy. <\/span>Regulatory Mechanisms in Biosystems<\/i>, <\/span>16<\/i>(1),
e25020. https:\/\/doi.org\/10.15421\/0225020<\/span><\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t

\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\tVynnychenko L.<\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t

Scopus Author ID:<\/strong> https:\/\/www.scopus.com\/authid\/detail<\/a><\/span><\/p>\n

h-index:<\/strong> <\/p>\n

ORCID ID:<\/strong> https:\/\/orcid.org\/<\/a><\/span><\/p>\n

1. Patalakha, O., Cherkashyna, L., Shklyar, A., Kyptenko, L., Yezhova, O., Vynnychenko, L., & Demikhova, N. (2023). Changes in the characteristics of oral fluid at the stages of treatment and rehabilitation of patients with mandibular fractures.<\/span><\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t

\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\tMoskalenko Y.<\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t

Scopus Author ID:<\/strong> https:\/\/www.scopus.com\/authid\/detail.uri?authorId= 57193309806<\/a><\/span><\/p>

h-index:<\/strong> 4<\/p>

ORCID ID:<\/strong> https:\/\/orcid.org\/0000-0002-5398-0298<\/a><\/span><\/p>

Research ID:<\/strong> ABG-1458-2020<\/p>

Google Scholar:<\/strong> https:\/\/scholar.google.com.ua\/citations?hl=uk&user=8tetJHcAAAAJ<\/a><\/span><\/p>

h-index:<\/strong> 4<\/p>

Research Gate:<\/strong> https:\/\/www.researchgate.net\/profile\/Yuliia-Moskalenko-2<\/a><\/span><\/p>

1. Medical discourse in pathological anatomy.
Moskalenko, R., Tatsenko, N., Romanyuk, A., Perelomova, O., Moskalenko, Y.
Georgian medical news, 2012, (206), pp. 63\u201366<\/p>

2. [Spermatogenic function under the influence of heavy metal salts and its correction by preparation Tivortin].
Romaniuk, A.M., Sauliak, S.V., Moskalenko, R.A., Moskalenko, I.V.
Likars’ka sprava \/ Ministerstvo okhorony zdorov’ia Ukra\u00efny, 2012, (1-2), pp. 123\u2013128<\/p>

3. [Vascular-parenchymal ratio of testes under correction of exposure to combinations of heavy metals salts].
Romaniuk, A.M., Moskalenko, I.V., Sauliak, S.V., Bonchev, S.D., Moskalenko, R.A.
Likars’ka sprava \/ Ministerstvo okhorony zdorov’ia Ukra\u00efny, 2013, (4), pp. 122\u2013127<\/p>

4. 12 years of fighting liposarcoma: a case report
Kononenko, M., Vynnychenko, I., Moskalenko, Y., Vynnychenko, O.
Wiadomosci lekarskie (Warsaw, Poland : 1960), 2017, 70(5), pp. 995\u2013997<\/p>

5. Primary multiple tumor with affection of the thyroid gland, uterus, urinary bladder, mammary gland and other organs
Romaniuk, \u0410., Lyndin, M., Smiyanov, V., …Sikora, V., Gladchenko, O.
Pathology Research and Practice, 2017, 213(5), pp. 574\u2013579<\/p>

6. Prostate cancer with intraluminal inclusions: The association of the immunophenotype with grade score
Pidddubnyi, A., Romaniuk, A., Radomychelski, I.-M., Moskalenko, Y., Moskalenko, R.A.
Iranian Journal of Pathology, 2019, 14(3), pp. 212\u2013222<\/p>

7. Case report of giant nonmetastatic gastrointestinal solid tumor without clinical manifestations in a middle-aged male patient
Vynnychenko, I., Kononenko, M., Smorodska, O., …Lyndin, M., Romaniuk, A.
Novosti Khirurgii, 2020, 28(5), pp. 597\u2013602<\/p>

8. Morphological and Crystal-Chemical Features of Macro- And Microcalcifications of Human Aorta
Radomychelski, I.-M., Piddubnyi, A., Danilchenko, S., …Moskalenko, Y., Moskalenko, R.
Microscopy and Microanalysis, 2021<\/p>

9. Smorodska O, Moskalenko Y, Vynnychenko I, Vynnychenko O, Kostuchenko V. Modern vector in treatment of patients with lung cancer: tyrosine kinase inhibitors in epidermal growth factor receptor mutations (literature review). perspekt. [Internet]. 2021Jun.18 [cited 2021Sep.20];26(2):4-11. Available from:\u00a0http:\/\/journals.uran.ua\/index.php\/2307-0404\/article\/view\/234379\u00a0<\/a><\/p>

10. Moskalenko Y, Smorodska O, Deineka V, Kravets O, Moskalenko R. Prognostic factors for recurrence in patients with surgically resected non-small cell lung cancer. Contemp Oncol (Pozn). 2022;26(3):239-246. doi: 10.5114\/wo.2022.120638. Epub 2022 Oct 24. PMID: 36381667; PMCID: PMC9641628.<\/p>

11. Moskalenko Y, Kurochkin A, Vynnychenko I, Kravets O, Piddubnyi A, Moskalenko R, Potapov O. Toluidine blue for the detection of sentinel lymph nodes in patients with thyroid cancer. Contemp Oncol (Pozn). 2022;26(4):259-267. doi: 10.5114\/wo.2022.124585. Epub 2022 Dec 30. PMID: 36816393; PMCID: PMC9933357.<\/p>

12. Piddubnyi, A., Kolomiiets, O., Danilchenko, S., Stepanenko, A., Moskalenko, Y., & Moskalenko, R. (2023). The Prospects of Using Structural Phase Analysis of Microcalcifications in Breast Cancer Diagnostics.\u00a0Diagnostics<\/em>,\u00a013<\/em>(4), 737.<\/p>

13. Kononenko M, Duzhiy I, Moskalenko Y. TARGETED THERAPY OF ANAPLASTIC THYROID CANCER. East. Ukr. Med. J. [Internet]. 2023Jun.18 [cited 2024Sep.14];11(2):113-20.<\/p>

14. Duzhiy I, Kononenko M, Moskalenko Y, Zhukova K. PAPILLARY CARCINOMA OF THE THYROGLOSSAL DUCT CYST: A CASE REPORT. East. Ukr. Med. J. [Internet]. 2023Jun.18 [cited 2024Sep.14];11(2):121-6.<\/p>

15. Moskalenko Y, Vynnychenko O, Sulaieva O, Moskalenko R. THE ROLE OF NEXT-GENERATION SEQUENCING IN LUNG CANCER DIAGNOSIS. East. Ukr. Med. J. [Internet]. 2023Sep.30 [cited 2024Sep.14];11(3):214-23.<\/p>

16. Moskalenko, Y. (2024). Biological mechanisms of resistance to immune checkpoint inhibitors and overcoming this resistance: Challenges in medical oncology. Regulatory Mechanisms in Biosystems, 15(1), 83-91. https:\/\/doi.org\/10.15421\/022412.<\/p>

17.\u00a0<\/span>Vynnychenko OI, Moskalenko YV. Prognostic impact
of body mass index on metastatic HER2-positive breast cancer survival.
\u0423\u043a\u0440\u0430\u0457\u043d\u0441\u044c\u043a\u0438\u0439 \u0440\u0430\u0434\u0456\u043e\u043b\u043e\u0433\u0456\u0447\u043d\u0438\u0439 \u0442\u0430 \u043e\u043d\u043a\u043e\u043b\u043e\u0433\u0456\u0447\u043d\u0438\u0439 \u0436\u0443\u0440\u043d\u0430\u043b. 2024; 32(3): 363\u2013376.
doi.org\/10.46879\/ukroj.3.2024.363-376.<\/span><\/p>

18. Vynnychenko O, Moskalenko Yu. Inflammatory
markers as predictors of efficacy of bevacizumab and tyrosine kinase inhibitors
therapy in metastatic non-small cell lung cancer patients. Eastern Ukrainian
Medical Journal. 2024; 12(4): 1007\u20131017. doi: https: \/\/doi.org\/10.21272\/eumj.2024.
<\/span><\/p>

19. Vynnychenko OI, Moskalenko YV, Moskalenko RA,
Dudnichenko OS, Rysovana LM, Hrankina SS. A single-center, cohort study of the
mutational profile of Ukrainian patients with non-small cell lung cancer.
\u0423\u043a\u0440\u0430\u0457\u043d\u0441\u044c\u043a\u0438\u0439 \u0440\u0430\u0434\u0456\u043e\u043b\u043e\u0433\u0456\u0447\u043d\u0438\u0439 \u0442\u0430 \u043e\u043d\u043a\u043e\u043b\u043e\u0433\u0456\u0447\u043d\u0438\u0439 \u0436\u0443\u0440\u043d\u0430\u043b. 2024; 32(4): 504\u2013517. doi:
https: \/\/doi.org\/10.46879\/ukroj.4.2024.504-517. <\/span><\/p>

20. Vynnychenko O, Moskalenko Y, Yazykov O,
Tymchenko I, Seleznov O, Sulaieva O, Moskalenko R. Prognostic role of STAT6 in
patients with non-small cell lung cancer. Regulatory Mechanisms in Biosystems.
2024; 15(4): 868\u2013874. doi: 10.15421\/0224125. <\/span><\/p>

21. Vynnychenko O, Moskalenko Yu, Moskalenko R. The
role of TP53 gene mutation in the survival of non-small cell lung cancer
patients. Eastern Ukrainian Medical Journal. 2025; 13(1): 245\u2013256.
doi.org\/10.21272\/eumj.2025. <\/span><\/p>

22. Vynnychenko O, Moskalenko Y, Moskalenko R.
Markers of inflammation as predictors of efficacy of trastuzumab therapy in
HER2-positive metastatic breast cancer patients. Regulatory Mechanisms in
Biosystems. 2025; 16(1): e25003. doi:10.15421\/0225003. <\/span><\/p>

23. Vynnychenko OI, Moskalenko YuV, Moskalenko RA.
STAT6 as a biomarker of trastuzumab resistance in patients with metastatic
HER2-positive breast cancer. \u0423\u043a\u0440\u0430\u0457\u043d\u0441\u044c\u043a\u0438\u0439 \u0440\u0430\u0434\u0456\u043e\u043b\u043e\u0433\u0456\u0447\u043d\u0438\u0439 \u0442\u0430 \u043e\u043d\u043a\u043e\u043b\u043e\u0433\u0456\u0447\u043d\u0438\u0439 \u0436\u0443\u0440\u043d\u0430\u043b.
2025; 33(1): 30\u201341. doi.org\/10.46879\/ukroj.1.2025.29-40.<\/span><\/p>

24. Vynnychenko O, Moskalenko R. Lung cancer in
Ukraine. \u041a\u043b\u0456\u043d\u0456\u0447\u043d\u0430 \u0442\u0430 \u043f\u0440\u043e\u0444\u0456\u043b\u0430\u043a\u0442\u0438\u0447\u043d\u0430 \u043c\u0435\u0434\u0438\u0446\u0438\u043d\u0430. 2025; 2(40): 6\u201313.
doi.org\/10.31612\/2616-4868.2.2025.01. <\/span><\/p>

25. Moskalenko Y., Kravets O.,
Kovchun V. Clinical outcomes of concurrent use of corticosteroids and immune
checkpoint inhibitors in oncology. Regul Mech Biosyst. 2025;16(2):<\/span>e25062<\/span> doi: 10.15421\/0225062 <\/span><\/p>

26. Moskalenko Y, Yazykov O, Vasylieva O, Smiian K, Ivakhniuk T, Budko H,
Moskalenko R. The Impact of Age on the Effectiveness of Immune Checkpoint
Inhibitors Therapy in Patients with Metastatic Non-Small-Cell Lung Cancer.
Geriatrics (Basel). 2025 Jun 27;10(4):85. doi: 10.3390\/geriatrics10040085.<\/span><\/p>

27. Kostiuchenko, V.,
Vynnychenko, I., Moskalenko, Y., & Pohorila, V. (2025). Detection of
postoperative recurrence in colorectal cancer: Exploring the value of liquid
biopsy.\u00a0<\/span>Regulatory Mechanisms in Biosystems<\/span><\/i>,\u00a016<\/i>(1), e25020. <\/span>https:\/\/doi.org\/10.15421\/0225020<\/span><\/a><\/p>

28. Kozakov D, Kobyliak N, Livshun S, Seleznov O, Koshyk O, Matvieieva A,
Shparyk Y, Kolesnik O, Moskalenko Y, Vynnychenko O, Moskalenko R, Kropyvko S,
Khmel A, Shkarupii B, Sulaieva O. Genetic alterations affect immune contexture
of non-small cell lung cancer: Ukrainian study. Front Med (Lausanne). 2025 Jul
30;12:1558016. doi: 10.3389\/fmed.2025.1558016.\u00a0<\/span><\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t

\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\tKovchun V.<\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t

Scopus Author ID:<\/span>\u00a0<\/span>57720919100<\/span><\/p>

h-index:<\/span>\u00a01<\/p>

ORCID ID:<\/span>\u00a0https:\/\/orcid.org\/0000-0002-9577-0272<\/p>

Google Scholar:https:\/\/scholar.google.com\/citations?view_op=list_works&hl=uk&user=ouTGJgcAAAAJ<\/span><\/p>

Research Gate:https:\/\/www.researchgate.net\/profile\/Kovchun-Viktor<\/span><\/p>

  1. Kovchun, V. Y., Smiianov, V. A., Kovchun, A. V., Kachkovska, V. V., & Sikora, V. Z. (2022). ULTRAMORPHOMETRIC CHARACTERISTICS OF ACINI AND MICROVASCULATURE OF THE PANCREAS IN THE PRESENCE OF MODERATE DEHYDRATION.\u00a0Wiad Lek<\/em>,\u00a075<\/em>(4), 998-1001.<\/li>
  2. Kachkovska, V., Kovchun, A., Kovchun, V., Klisch, I., Marchuk, O., Dudchenko, I., & Prystupa, L. (2023). ER22\/23EK AND TTH111I POLYMORPHISMS IN THE GLUCOCORTICOID RECEPTOR GENE IN PATIENTS WITH BRONCHIAL ASTHMA WITH REGARD TO THE AGE OF ONSET.\u00a0Georgian<\/em> Medical News<\/em>, (334), 94-97.<\/li>

  3. Kovchun, A., Kovchun, V., Kachkovska, V., Prystupa, L. (2023). The role of Low-Dose CT scan in the early diagnosis of malignant neoplasms of different localization. European Respiratory Journal, Sep 2023, 62 (suppl 67) PA5348; DOI: 10.1183\/13993003.congress-2023.<\/p><\/li>

  4. Moskalenko Y.,
    Kravets O., Kovchun V. Clinical outcomes of concurrent use of corticosteroids
    and immune checkpoint inhibitors in oncology. Regul Mech Biosyst. 2025;16(2):<\/span>e25062<\/span> doi: 10.15421\/0225062.<\/span><\/p><\/li><\/ol><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t

    \n\t\t\t\t\t
    \n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\tLakhtaryna R.<\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t

    Scopus Author ID:<\/strong> https:\/\/www.scopus.com\/authid\/<\/a><\/span><\/p>

    h-index:<\/strong> 0<\/p>

    ORCID ID:<\/strong> https:\/\/orcid.org\/0009-0001-8017-788X<\/span><\/a><\/p>

    https:\/\/www.researchgate.net\/profile\/Ruslana-Lakhtaryna<\/p>

    https:\/\/scholar.google.com\/citations?view_op=metrics_intro&hl=uk<\/p>

    1.\u00a0Savchenko T, Lakhtaryna R, Denysenko A, Dovbysh A, Coupland SE,
    Moskalenko R. An Information-Extreme Algorithm for Universal Nuclear
    Feature-Driven Automated Classification of Breast Cancer Cells. Diagnostics
    (Basel). 2025 May 30;15(11):1389. doi: 10.3390\/diagnostics15111389.<\/span><\/p>

    \u00a0<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

    \n\t\t\t\t\t\t
    \n\t\t\t\t\t
    \n\t\t\t
    \n\t\t\t\t\t\t
    \n\t\t\t\t\t\t
    \n\t\t\t\t\t
    \n\t\t\t
    \n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

    SCIENTIFIC WORK Department of Oncology and Radiology public information Publications Scopus General list of publications 1.Rare complication of the Lewis operation | Redkoe oslozhnenie operatsii L’iuisa.Vinnichenko, A.A., Vinnichenko, I.A., Moskalenko, V.L., Korobe\u01d0nik, V.I. Klinicheskaya Khirurgiya, 1990, (10), pp. 53 2. Experience with gastro- and enterostomy in esophageal obstruction | Opyt gastro- i \u00e9nterostomii pri neprokhodimosti […]<\/p>\n","protected":false},"author":3,"featured_media":0,"parent":13653,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"elementor_header_footer","meta":{"lazy_load_responsive_images_disabled":false,"footnotes":""},"class_list":["post-13659","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/oncology.med.sumdu.edu.ua\/en\/wp-json\/wp\/v2\/pages\/13659","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oncology.med.sumdu.edu.ua\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/oncology.med.sumdu.edu.ua\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/oncology.med.sumdu.edu.ua\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/oncology.med.sumdu.edu.ua\/en\/wp-json\/wp\/v2\/comments?post=13659"}],"version-history":[{"count":9,"href":"https:\/\/oncology.med.sumdu.edu.ua\/en\/wp-json\/wp\/v2\/pages\/13659\/revisions"}],"predecessor-version":[{"id":15744,"href":"https:\/\/oncology.med.sumdu.edu.ua\/en\/wp-json\/wp\/v2\/pages\/13659\/revisions\/15744"}],"up":[{"embeddable":true,"href":"https:\/\/oncology.med.sumdu.edu.ua\/en\/wp-json\/wp\/v2\/pages\/13653"}],"wp:attachment":[{"href":"https:\/\/oncology.med.sumdu.edu.ua\/en\/wp-json\/wp\/v2\/media?parent=13659"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}